By Marie Rosenthal
The FDA will allow Sloan Pharma to reintroduce tegaserod (Zelnorm), a twice-daily oral treatment for irritable bowel syndrome with constipation (IBS-C) in women younger than 65 years of age.
The FDA originally approved tegaserod in 2002 for the treatment of IBS-C in women. Despite being the market leader in IBS-C, it was withdrawn voluntarily by Novartis in 2007 due to an increased risk for having a myocardial infarction, stroke or unstable angina.
Tegaserod remained